File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group

TitleAllogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group
Authors
Issue Date2014
Citation
Bone Marrow Transplantation, 2014, v. 49, p. 902-906 How to Cite?
AbstractEighteen patients (men=14; women=4) with natural killer (NK)/T-cell lymphomas (CR1, N=9; CR2, N=7; PR, N=1; progressive disease, N=1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N=14; reduced intensity, N=4) were analyzed. With a median follow-up of 20.5 months, the 5-year OS was 57% and 5-year EFS was 51%. The use of the SMILE regimen pre-HSCT was the most important positive prognostic indicator, resulting in significantly superior OS and EFS (P<0.01). Acute GVHD had a significant negative impact on OS (P=0.03). CR1 and CR2 patients had similar survivals, but all patients who were not transplanted in remission died. Chronic GVHD, International Prognostic Index, disease stage, primary sites of involvement, conditioning regimen and source of HSC did not affect survival. Although allogeneic HSCT leads to reasonable survival for NK/T-cell lymphoma patients, results need to be compared with those in patients receiving L-asparaginase-containing regimens. Novel prognostic models incorporating biomarkers, such as circulating EBV DNA, are needed to identify high-risk patients who may benefit from allogeneic HSCT.
Persistent Identifierhttp://hdl.handle.net/10722/203077
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTse, EWCen_US
dc.contributor.authorChan, SYTen_US
dc.contributor.authorKoh, LPen_US
dc.contributor.authorChng, WJen_US
dc.contributor.authorKim, WSen_US
dc.contributor.authorTang, Ten_US
dc.contributor.authorLim, STen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2014-09-19T11:29:41Z-
dc.date.available2014-09-19T11:29:41Z-
dc.date.issued2014en_US
dc.identifier.citationBone Marrow Transplantation, 2014, v. 49, p. 902-906en_US
dc.identifier.urihttp://hdl.handle.net/10722/203077-
dc.description.abstractEighteen patients (men=14; women=4) with natural killer (NK)/T-cell lymphomas (CR1, N=9; CR2, N=7; PR, N=1; progressive disease, N=1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N=14; reduced intensity, N=4) were analyzed. With a median follow-up of 20.5 months, the 5-year OS was 57% and 5-year EFS was 51%. The use of the SMILE regimen pre-HSCT was the most important positive prognostic indicator, resulting in significantly superior OS and EFS (P<0.01). Acute GVHD had a significant negative impact on OS (P=0.03). CR1 and CR2 patients had similar survivals, but all patients who were not transplanted in remission died. Chronic GVHD, International Prognostic Index, disease stage, primary sites of involvement, conditioning regimen and source of HSC did not affect survival. Although allogeneic HSCT leads to reasonable survival for NK/T-cell lymphoma patients, results need to be compared with those in patients receiving L-asparaginase-containing regimens. Novel prognostic models incorporating biomarkers, such as circulating EBV DNA, are needed to identify high-risk patients who may benefit from allogeneic HSCT.en_US
dc.languageengen_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.titleAllogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Groupen_US
dc.typeArticleen_US
dc.identifier.emailTse, EWC: ewctse@hku.hken_US
dc.identifier.emailLie, AKW: akwlie@hkucc.hku.hken_US
dc.identifier.emailKwong, YL: ylkwong@hku.hken_US
dc.identifier.authorityTse, EWC=rp00471en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.doi10.1038/bmt.2014.65en_US
dc.identifier.pmid24777195-
dc.identifier.hkuros236637en_US
dc.identifier.volume49en_US
dc.identifier.spage902en_US
dc.identifier.epage906en_US
dc.identifier.isiWOS:000338878100006-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats